# Ibudilast PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ibudilast

> The next catalyst for ibudilast, sponsored by MEDICINOVA INC (MNOV), is its primary completion, April 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ibudilast |
| Codes | MN-166 |
| Sponsor | MEDICINOVA INC (MNOV) https://sec-api.dev/companies/mnov/catalysts |
| Indications | [Amyotrophic Lateral Sclerosis](https://sec-api.dev/indications/amyotrophic-lateral-sclerosis) |
| Modality |  |
| FDA designations | fast track, orphan, priority review |

## Timeline

### Jun 2022: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2024-11-13, last confirmed 2025-08-22.
- SEC Form 10-Q (accession 0000950170-24-126343): "In June 2022, we announced positive top-line results from this Phase 2 clinical trial in which MN-166 (ibudilast) demonstrated large improvements compared to placebo for all four clinical endpoints analyzed." https://www.sec.gov/Archives/edgar/data/1226616/000095017024126343/mnov-20240930.htm
- SEC registration statement (S-1) (accession 0001193125-25-186446): "In June 2022, we announced positive top-line results from this Phase 2 clinical trial." https://www.sec.gov/Archives/edgar/data/1226616/000119312525186446/d163359ds1.htm
- SEC Form 10-K (accession 0000950170-25-023301): "In June 2022, we announced positive top-line results from this Phase 2 clinical trial." https://www.sec.gov/Archives/edgar/data/1226616/000095017025023301/mnov-20241231.htm

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Amyotrophic Lateral Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04057898 (Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor MediciNova." https://clinicaltrials.gov/study/NCT04057898

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Amyotrophic Lateral Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04057898 (Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor MediciNova." https://clinicaltrials.gov/study/NCT04057898

## Same indication

- [ARGX-119](https://sec-api.dev/pdufa/argx-119) (ARGX)
- [Dazucorilant 300 mg](https://sec-api.dev/pdufa/dazucorilant) (CORT)
- [ION363](https://sec-api.dev/pdufa/ion363) (IONS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ibudilast.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ibudilast PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ibudilast

```bibtex
@misc{secapidev_pdufa_ibudilast_20261116,
  title        = {Ibudilast PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ibudilast}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ibudilast_20261116","title":"Ibudilast PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ibudilast","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
